Mirum Pharmaceuticals Inc
NASDAQ:MIRM 3:59:52 PM EDT
Earnings Announcements
Mirum Pharmaceuticals Q2 Loss Per Share $0.84
Published: 08/04/2022 20:42 GMT
Mirum Pharmaceuticals Inc (MIRM) - Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update.
Net Product Sales for Livmarli(® )(maralixibat) Oral Solution Totaled $17.5 Million in Q2 of 2022.
Q2 Loss per Share $0.84.
Net Product Sales for Livmarli(® )(maralixibat) Oral Solution Totaled $17.5 Million in Q2 of 2022.
Q2 Loss per Share $0.84.
Revenue is expected to be $20.32 Million
Adjusted EPS is expected to be -$1.05
Next Quarter Revenue Guidance is expected to be $21 Million
Next Quarter EPS Guidance is expected to be -$0.93
More details on our Analysts Page.
Adjusted EPS is expected to be -$1.05
Next Quarter Revenue Guidance is expected to be $21 Million
Next Quarter EPS Guidance is expected to be -$0.93
More details on our Analysts Page.